RxDoctor Payments Data

Adam Dao, MD

Cornea and External Diseases Specialist · San Diego, CANPI 1770870446

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 3 manufacturers reported payments, led by AbbVie at 44.8% of the total. Reporting peaked in 2019 at $84 and has fallen 71.8% since, to $24 in 2025. That places this record below the midpoint for cornea and external diseases specialist clinicians in CA, where the typical reported total is $4,024.

$290in general payments, 2019–2025

Across 14 payments — averaging $20.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$130
  • Alcon$118
  • Johnson & Johnson Surgical Vision, Inc.$43

What the payments were for

  • Food & beverage$290100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie7$130
Alcon5$118
Johnson & Johnson Surgical Vision, Inc.2$43

How this compares

$290 in reported general payments places this provider in the 5th percentile of 50 cornea and external diseases specialist providers in California.

See all cornea and external diseases specialist providers in California

Medicare billing

Part B allowed, 2024
$2,342,541
Medicare patients
736
Services billed
14,170

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost101$60,979
ValacyclovirValacyclovir Hcl36$5,989
RhopressaNetarsudil Mesylate12$4,462
Prednisolone Acetate85$3,273
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol14$1,840
MoxifloxacinMoxifloxacin Hcl82$1,746
Difluprednate20$1,636
Latanoprost153$1,521
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat66$1,440
Timolol Maleate116$1,207
Brinzolamide11$999
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha22$213
Ketorolac Tromethamine14$161
Doxycycline Hyclate11$148

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$130$60,979101 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 5th percentile of 50 cornea and external diseases specialist providers in California.

Other cornea and external diseases specialist in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →